Atopic Dermatitis Market Sales to Hit $5.6 Billion by 2022 Combined for Nine Major Countries

Nov 10, 2015, 11:45 ET from ReportsnReports

PUNE, India, November 10, 2015 /PRNewswire/ --

New market research titled "EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2024" says atopic dermatitis therapeutic sales in the nine major markets (9MM) are forecast to increase to $5.6 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 3.8%.

Complete report on Atopic Dermatitis - Epidemiology Forecast to 2024 spread across 42 pages, focusing on the US, France Germany, Italy, Spain, UK, Japan, China and India as well as supported with 9 tables and 5 figures is now available at .

Atopic dermatitis or atopic eczema is the most common type of eczema. Atopic dermatitis is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Though the condition affects people of all ages, it is primarily common among infants and children. Risk factors for atopic dermatitis are broadly classified as modifiable and non-modifiable. Modifiable risk factors include inhalant allergens, food allergens, and newborns not being exclusively breastfed; non-modifiable risk factors include young age and genetics or heritability. In addition, the most common comorbidities associated with the atopic dermatitis such as atopic disorders and psychological disorders contribute significantly to the clinical occurrence of atopic dermatitis.

Epidemiologists forecast that the one-year total prevalent cases of atopic dermatitis in the 9MM will increase from 66,289,178 cases in 2014 to 67,630,097 cases in 2024 with an annual growth rate (AGR) of 0.20% and the prevalent cases of atopic dermatitis in the 9MM from 2014-2024 using country-specific studies that provided one-year total prevalence of atopic dermatitis in these markets obtained through symptom-based surveys.

The Atopic Dermatitis EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for atopic dermatitis in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, China, and India). It includes a 10-year epidemiological forecast of the one-year prevalent cases of atopic dermatitis segmented by sex, age (in one-year increments beginning at 0 and ending at 19 years and also in five-year increments beginning at 20 years and ending at =85 years), and severity in these markets. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM. Order a copy of this report @ .

Another newly published market research titled Contact Dermatitis - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Contact dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Contact Dermatitis Pipeline Review research report of 54 pages is available at .

Explore more reports on Pharmaceuticals market at .

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  




G+ / Google Plus:



Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441

SOURCE ReportsnReports